Get the Stockscreener App
0.0941
6.21%
0.0055
Propanc Biopharma Inc stock is traded at $0.0941, with a volume of 677.17K.
It is up +6.21% in the last 24 hours and down -8.64% over the past month.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
See More
Previous Close:
$0.0886
Open:
$0.0948
24h Volume:
677.17K
Relative Volume:
0.18
Market Cap:
$2.06M
Revenue:
-
Net Income/Loss:
$-66.07M
P/E Ratio:
-0.00695
EPS:
-13.5424
Net Cash Flow:
$-3.11M
1W Performance:
-8.64%
1M Performance:
-8.64%
6M Performance:
-88.81%
1Y Performance:
+0.00%
1-Day Range:
$0.0904
$0.098
1-Week Range:
$0.0855
$0.1074
52-Week Range:
$0.0855
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
Name
Propanc Biopharma Inc
Sector
Industry
Phone
61-03-9882-0780
Address
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Compare PPCB vs MOBBW, GOODO, SHMD, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
2.5501 | 3.41B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
20.24 | 372.90M | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
5.99 | 346.81M | 52.15M | -21.46M | 0 | -0.4675 |
PSNYW
Polestar Automotive Holding Uk
|
3.21 | 278.44M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.96 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc Stock (PPCB) Latest News
The supply chain story behind Propanc Biopharma (PPCB) earnings |Analyst Ratings - newser.com
Propanc Biopharma announces up to $100M strategic financing from Hexstone Capital - MSN
[EFFECT] Propanc Biopharma, Inc. SEC Filing - Stock Titan
Trending Industry Today: Propanc Biopharma Leads Gains In ETH-Holding Companies Stocks - Moomoo
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB - The Joplin Globe
The selling point was good, but there's still a loss. This money can't be used to average down. - Moomoo
Propanc Biopharma Incfiles to offer resale of up to 15 million shares of common stock by selling stockholderSEC filing - marketscreener.com
Propanc Biopharma (PPCB) files S-1 for 15M-share resale from Series C preferred - Stock Titan
PPCB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Propanc Biopharma (PPCB) approves restricted grants, reverse split 1:10–1:30 - Stock Titan
Propanc Biopharma, Inc. (PPCB) - Minichart
What should investors watch in Propanc Biopharma (PPCB) Stock | Price at $0.10, Down 3.30%Risk Reward Ratio - Xã Châu Thành
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - BioSpace
Propanc extends 17-year Spain research tie to study aging and cancer - Stock Titan
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer - GlobeNewswire
Propanc Biopharma (PPCB) approves 33M shares and 1:10–1:30 reverse split - Stock Titan
Propanc & Fyonibio Launch Assay for Phase 1b Human Study - The Clinical Trial Vanguard
PPCB Should I Buy - Intellectia AI
Propanc Biopharma (PPCB) Stock Analysis Report | Financials & Insights - Benzinga España
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy - Bitget
13% survival in pancreatic cancer; Propanc therapy hits >85% tumor inhibition - Stock Titan
Propanc Biopharma signs contract for Phase 1b cancer trial assay By Investing.com - Investing.com Canada
Propanc Biopharma contracts FyoniBio for drug assay development By Investing.com - Investing.com South Africa
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study - Bitget
Propanc Biopharma contracts FyoniBio for drug assay development - Investing.com
Propanc Biopharma signs contract for Phase 1b cancer trial assay - Investing.com
Propanc Biopharma Executes Service Agreement with FyoniBio - GlobeNewswire
Propanc Biopharma | 424B3: Prospectus - Moomoo
Propanc Biopharma's lead asset PRP shows >85% tumor growth inhibition in preclinical pancreatic models - marketscreener.com
Propanc Biopharma highlights potential of lead asset PRP - TipRanks
Propanc Biopharma’S Lead Asset Prp Shows >85% Tumor Growth Inhibition In Preclinical Pancreatic Models - TradingView
Deadliest cancer stuck at 13% survival: new PRP therapy targets spread - Stock Titan
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement By Investing.com - Investing.com South Africa
Propanc Biopharma Announces Board Change and New Appointment - TipRanks
Propanc Biopharma appoints Dr. Ralf Brandt to board following Dr. Kenyon’s retirement - Investing.com Nigeria
Propanc Biopharma (PPCB) adds oncology expert Ralf Brandt to board as Kenyon retires - Stock Titan
Propanc Biopharma | EFFECT: Others - Moomoo
Propanc Biopharma files four new patent applications for cancer treatment By Investing.com - Investing.com South Africa
Propanc Biopharma files four new patent applications for cancer treatment - Investing.com
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results - The Manila Times
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Certain Warrants of Propanc Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 10-FEB-2026. - marketscreener.com
Propanc Biopharma Inc Stock (PPCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.70%
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):